Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum(II) does not correlate with the platination level or with the formation or removal of DNA adducts

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 479-485

  Vendrik, Cornelis P J ^a   Fichtinger Schepman, Anne Marie J ^b   Van Dijk Knijnenburg, Wilhelmina C M ^b   De Jong, Wim H ^c   Van Der Minnen, Anke C E ^c   De Groot, Gerard ^c   Berends, Geert Frits ^b   Steerenberg, Peter A ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TNO   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Immunocytoma; Platinum DNA adducts; Resistance; Sensitivity

Indexed keywords

CISPLATIN; PLATINUM;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL LINE; CONTROLLED STUDY; DNA BINDING; DRUG RESISTANCE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOCYTOMA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PARENCHYMA; PRIORITY JOURNAL; RAT;

ANIMALS; CISPLATIN; DNA ADDUCTS; DRUG RESISTANCE, NEOPLASM; IMMUNOGLOBULIN M; LYMPHOMA, SMALL LYMPHOCYTIC; NEOPLASM TRANSPLANTATION; RATS;

EID: 0031016942     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050602     Document Type: Article

References (21)

1. De Jong WH, Steerenberg PA, Vos JG, Bulten EJ, Verbeek F, Kruizinga W, Ruitenberg EJ (1983) Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclo-hexane-platinum(II) sulfate, and of cis-diamminedichloro-platinum(II) in an immuno-cytoma model in the LOU/M rat. Cancer Res 43: 4927-4934
2. Steerenberg PA, Vendrik CPJ, Jong WH de, Groot G de, Fichtinger-Schepman AM, Scheefhals APH, Schornagel JH (1988) Resistance and cross-resistance of the IgM-immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin. Cancer Chemother Pharmacol 22: 51-57
3. Fichtinger-Schepman AMJ, Veer JL van der, Hartog JHJ den, Lohman PHM, Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707-713
4. Fichtinger-Schepman AMJ, Oosterom AT van, Lohman PHM, Berends F (1987) cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 47: 3000-3004
5. Hromas RA, North JA, Bums CP (1986) Cis-platinum uptake in L1210 leukemia cells resistant and sensitive to the drug. Proc Am Assoc Cancer Res 27: 263
6. Shionoya S, Lu Y, Scanlon KJ (1986) Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Res 46: 3445-3448
7. Richon VM, Schulte N, Eastman A (1987) Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia. Cancer Res 47: 2056-2061
8. Andrews PA, Murphy MP, Howell SB (1986) Characterization of cisplatin-resistant colo 316 human ovarian carcinoma cells. Proc Am Assoc Cancer Res 27: 289
9. Bedford P, Walker MC, Sharma HL, Perera A, McAuliffe CA, Masters JRW, Hill BT (1987) Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II). Chem Biol Intract 61: 1-15
10. Hansson J, Fichtinger-Schepman AMJ, Edgren M, Ringborg U (1991) Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin. Eur J Cancer 27: 1039-1045
11. Hospers GAK, Meijer C, Leij L de, Uges DRA, Mulder NH, Vries EGE de (1990) A study of human small-cell lung carcinoma (HSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (cddp) resistance. Int J Cancer 46: 138-144
12. Eastman A, Schulte N, Sheibani N, Sorenson CM (1988) Mechanisms of resistance to platinum drugs. In: Nicolini M (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff, Boston, pp 178-196
13. Fichtinger-Schepman AMJ, Vendrik CPJ, Dijk-Knijnenburg WCM van, Jong WH de, Minnen ACE van der, Claessen AME, Velde-Visser SD van der, Groot G de, Wubs KL, Steerenburg PA, Schornagel JH, Berends F (1989) Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or resistant immunoglobulin M immunocytoma. Cancer Res 49: 2862-2867
14. Groot G de, Wubs KL (1987) A simple enzymatic digestion procedure of intact tissue samples in pharmacokinetic drug analysis. J Anal Toxicol 11: 175-178
15. Fichtinger-Schepman AMJ, Veer JL van der, Lohman PHM, Reedijk J (1984) A simple method for the inactivation of monofunctionally DNA-bound cis-diamminedichloroplatinum(II). J Inorg Biochem 21: 103-112
16. Fichtinger-Schepman AMJ, Dijt FJ, Jong WH de, Oosterom AT van, Berends F (1988) In vivo cis-diamminedichloroplatinum(II)-DNA aduct formation and removal as measured with immunochemical techniques. In: Nicolini M (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff, Boston, pp 32-46
17. Mellon I, Bohr VA, Smith CA, Hanawalt PC (1986) Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci USA 83: 8878-8882
18. Mellon I, Spivak G, Hanawalt PC (1987) selective removal of transcription blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell 51: 241-249
19. Bohr VA, Phillips DH, Hanawalt PC (1985) Heterogeneous DNA damage and repair in the mammalian genome. Cancer Res 47: 6426-6431
20. Shellard SA, Fichtinger-Schepman AMJ, Laza JS, Hill BT (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4: 491-500
21. Shellard SA, Hosking LK, Hill BT (1991) An anomalous relationship between cisplatin sensitivity and formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res 51: 4557-4564